{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:21:18Z","timestamp":1786123278288,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.fjurol.2026.103148","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:29:23Z","timestamp":1781652563000},"page":"103148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of homologous recombination repair genes alterations in metastatic castration-resistant prostate cancer, a multicentric study"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6179-3396","authenticated-orcid":false,"given":"Pierre","family":"Allaume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Raby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-6477","authenticated-orcid":false,"given":"Maya","family":"Nourieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Lespagnol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"P\u00e9ricart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Tantot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Decaussin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Callens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Descotes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-077X","authenticated-orcid":false,"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Rioux-Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne-Florence","family":"Kammerer-Jacquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2026.103148_bib0150","unstructured":"International Agency for Research on Cancer. Prostate cancer: fact sheet. [Internet]. [cited 2024 Nov 14]. Available from: https:\/\/gco.iarc.who.int\/today\/."},{"key":"10.1016\/j.fjurol.2026.103148_bib0155","unstructured":"Sant\u00e9 Publique France [Internet]. [cited 2024 Oct 26]. Available from: https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/cancers."},{"issue":"10","key":"10.1016\/j.fjurol.2026.103148_bib0160","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.fjurol.2026.103148_bib0165","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.fjurol.2026.103148_bib0170","doi-asserted-by":"crossref","first-page":"102710","DOI":"10.1016\/j.fjurol.2024.102710","article-title":"Cancer Committee Guidelines - Update 2024-2026: prostate cancer - management of metastatic disease and castration resistance","volume":"34","author":"Ploussard","year":"2024","journal-title":"Fr J Urol"},{"key":"10.1016\/j.fjurol.2026.103148_bib0175","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"7","key":"10.1016\/j.fjurol.2026.103148_bib0180","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","article-title":"Metastatic castration-resistant prostate cancer: advances in treatment and symptom management","volume":"25","author":"Kulasegaran","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"14","key":"10.1016\/j.fjurol.2026.103148_bib0185","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.fjurol.2026.103148_bib0190","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","article-title":"Germline BRCA mutations denote a clinicopathologic subset of prostate cancer","volume":"16","author":"Gallagher","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103148_bib0195","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.fjurol.2026.103148_bib0200","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"De Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.fjurol.2026.103148_bib0205","first-page":"708","article-title":"Efficacy of PARP inhibitors as maintenance therapy for metastatic castration-resistant prostate cancer: a meta-analysis of randomized controlled trials","volume":"35","author":"Niazi","year":"2021","journal-title":"Oncology (Williston Park)"},{"issue":"10","key":"10.1016\/j.fjurol.2026.103148_bib0210","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.3390\/curroncol30100669","article-title":"A meta-analysis of randomized clinical trials assessing the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer","volume":"30","author":"Alameddine","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.fjurol.2026.103148_bib0215","doi-asserted-by":"crossref","first-page":"216367","DOI":"10.1016\/j.canlet.2023.216367","article-title":"PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer","volume":"577","author":"Slootbeek","year":"2023","journal-title":"Cancer Lett"},{"issue":"9","key":"10.1016\/j.fjurol.2026.103148_bib0220","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.fjurol.2026.103148_bib0225","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.euo.2023.09.001","article-title":"Poly (ADP-ribose) polymerase inhibitors have comparable efficacy with platinum chemotherapy in patients with BRCA-positive metastatic castration-resistant prostate cancer. a systematic review and meta-analysis","volume":"7","author":"Fazekas","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2026.103148_bib0230","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2022.09.010","article-title":"Emergence of BRCA reversion mutations in patients with metastatic castration-resistant prostate cancer after treatment with rucaparib","volume":"83","author":"Loehr","year":"2023","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103148_bib0235","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1002\/cam4.5333","article-title":"The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: the multi-institutional observational ZENSHIN study","volume":"12","author":"Uemura","year":"2023","journal-title":"Cancer Med"},{"issue":"10398","key":"10.1016\/j.fjurol.2026.103148_bib0240","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.fjurol.2026.103148_bib0245","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.fjurol.2026.103148_bib0250","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.fjurol.2026.103148_bib0255","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","article-title":"Tumor Genomic Testing for>4,000 men with metastatic castration-resistant prostate cancer in the Phase III Trial PROfound (Olaparib)","volume":"28","author":"Hussain","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.fjurol.2026.103148_bib0260","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","volume":"2017","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.fjurol.2026.103148_bib0265","doi-asserted-by":"crossref","first-page":"e2300628","DOI":"10.1200\/PO.23.00628","article-title":"Prospective study of homologous recombination repair gene mutation prevalence in patients with advanced prostate cancer from Latin America: challenges and future approaches","volume":"8","author":"Manneh","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103148_bib0270","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clgc.2023.05.012","article-title":"Germline DNA repair genes pathogenic variants among Mexican patients with prostate cancer","volume":"21","author":"Ch\u00e1varri-Guerra","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.fjurol.2026.103148_bib0275","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12885-021-09082-y","article-title":"Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets","volume":"22","author":"Lai","year":"2022","journal-title":"BMC Cancer"},{"issue":"Suppl. 6","key":"10.1016\/j.fjurol.2026.103148_bib0280","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1200\/JCO.2020.38.6_suppl.182","article-title":"Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC)","volume":"38","author":"Shi","year":"2020","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.fjurol.2026.103148_bib0285","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1158\/1078-0432.CCR-21-3577","article-title":"Olaparib efficacy in patients with metastatic castration-resistant prostate cancer and BRCA1, BRCA2, or ATM alterations identified by testing circulating tumor DNA","volume":"29","author":"Matsubara","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.fjurol.2026.103148_bib0290","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.3390\/diagnostics13162676","article-title":"Deep learning methodologies applied to digital pathology in prostate cancer: a systematic review","volume":"13","author":"Rabilloud","year":"2023","journal-title":"Diagnostics (Basel)"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026000793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026000793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:36:35Z","timestamp":1786113395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393026000793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950393026000793"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103148","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of homologous recombination repair genes alterations in metastatic castration-resistant prostate cancer, a multicentric study","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103148"}}